Da kommt sicher was! WKN 902213
Anzeige
Meldung des Tages: Der nächste Gold-Hebel? 200 Meter Treffer, volle Kassen – warum diese Aktie jetzt auffällt
Geron schon halbes Tagesvolumen!
Beiträge:
5
Zugriffe: 5.646 / Heute: 1
Zugriffe: 5.646 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
Kerry stumps for stem cell research
By Val Brickates Kennedy, CBS.MarketWatch.com
Last Update: 12:14 PM ET Oct. 4, 2004
E-mail it | Print | Alert | Reprint | RSS
BOSTON (CBS.MW) -- Democratic presidential candidate Sen. John Kerry plans to plug increasing federal funding for stem cell research during a campaign push through New Hampshire on Monday.
Free! Sign up here to receive our After the Bell Report e-Newsletter!
TRADING CENTER
INFORMATION FOR GERN:
Create an alert for GERN
Add GERN to my portfolio
More cool charts on GERN
Discuss GERN
NEWS FOR GERN
Kerry to plug stem cell research
Geron, Procter & Gamble in telomerase license deal
Genentech closes lower pre-earnings
More news for GERN
Quote & News Charts Financials Analysts Options SEC Filings
TRACK THESE TOPICS
My Portfolio Alerts
Company: Aastrom Biosciences Inc Add
Create
Company: Stemcells Inc Add
Create
Company: Geron Corporation Add
Create
Company: LifeCell Corp Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
Kerry is scheduled to hold a town meeting on the subject in Hampton, N.H., where he will be joined by actor Michael J. Fox, who suffers from Parkinson's disease. Fox has been a tireless advocate for stem cell research, which many believe may someday offer keys to better treatment, or even a cure, for such devastating diseases as Parkinson's and Alzheimer's.
Kerry is expected to criticize the Bush administration's long-standing policy of denying federal research funds to organizations and companies that engage in research on stem cells derived from cellular lines that were not in existence prior to 2001. The issue is controversial because stem cells are derived from days-old donated human embryos, which are destroyed in the culling process.
The Kerry campaign also plans to launch a national ad campaign on the subject on Monday.
Stem cell research proponents have argued that research must use newer cellular lines as many of the administration-approved lines have become contaminated. Supporters of the Bush administration's position maintain that new cellular lines should not be created as that would involve the destruction of human embryos.
Kerry and the Democratic Party have argued that the Bush administration's position on federal funding for stem cell research is an example of the administration imposing its own religious views on the scientific community.
Shares of several stem cell researchers were trading higher on Monday. Tiny Aastrom Biosciences (ASTM: news, chart, profile) gained 9.78 percent to $1.01, while StemCells Inc.(STEM: news, chart, profile) advanced 8.33 percent to $1.69. Also gaining were Geron (GERN: news, chart, profile), up 4.83 percent to $6.29, and LifeCell (LIFC: news, chart, profile), up 4.75 percent to $10.55.
By Val Brickates Kennedy, CBS.MarketWatch.com
Last Update: 12:14 PM ET Oct. 4, 2004
E-mail it | Print | Alert | Reprint | RSS
BOSTON (CBS.MW) -- Democratic presidential candidate Sen. John Kerry plans to plug increasing federal funding for stem cell research during a campaign push through New Hampshire on Monday.
Free! Sign up here to receive our After the Bell Report e-Newsletter!
TRADING CENTER
INFORMATION FOR GERN:
Create an alert for GERN
Add GERN to my portfolio
More cool charts on GERN
Discuss GERN
NEWS FOR GERN
Kerry to plug stem cell research
Geron, Procter & Gamble in telomerase license deal
Genentech closes lower pre-earnings
More news for GERN
Quote & News Charts Financials Analysts Options SEC Filings
TRACK THESE TOPICS
My Portfolio Alerts
Company: Aastrom Biosciences Inc Add
Create
Company: Stemcells Inc Add
Create
Company: Geron Corporation Add
Create
Company: LifeCell Corp Add
Create
Get Breaking News sent directly to your inbox
Create A Portfolio | Create An Alert
Kerry is scheduled to hold a town meeting on the subject in Hampton, N.H., where he will be joined by actor Michael J. Fox, who suffers from Parkinson's disease. Fox has been a tireless advocate for stem cell research, which many believe may someday offer keys to better treatment, or even a cure, for such devastating diseases as Parkinson's and Alzheimer's.
Kerry is expected to criticize the Bush administration's long-standing policy of denying federal research funds to organizations and companies that engage in research on stem cells derived from cellular lines that were not in existence prior to 2001. The issue is controversial because stem cells are derived from days-old donated human embryos, which are destroyed in the culling process.
The Kerry campaign also plans to launch a national ad campaign on the subject on Monday.
Stem cell research proponents have argued that research must use newer cellular lines as many of the administration-approved lines have become contaminated. Supporters of the Bush administration's position maintain that new cellular lines should not be created as that would involve the destruction of human embryos.
Kerry and the Democratic Party have argued that the Bush administration's position on federal funding for stem cell research is an example of the administration imposing its own religious views on the scientific community.
Shares of several stem cell researchers were trading higher on Monday. Tiny Aastrom Biosciences (ASTM: news, chart, profile) gained 9.78 percent to $1.01, while StemCells Inc.(STEM: news, chart, profile) advanced 8.33 percent to $1.69. Also gaining were Geron (GERN: news, chart, profile), up 4.83 percent to $6.29, and LifeCell (LIFC: news, chart, profile), up 4.75 percent to $10.55.
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Geron Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 399 | + 12,3 % bei Geron (902213) Was ist los? o. T. | Biomedi | Vassago | 26.02.25 18:36 | |
| 3 | Geron (902213) mit NEWS = 500% in 2 Wochen | Biomedi | Biomedi | 01.10.19 12:57 | ||
| 3 | 10 | Geron WKN:902213 jetzt kaufen ! | Chalifmann3 | Trinkfix | 25.06.12 07:43 | |
| 4 | Geron schon halbes Tagesvolumen! | Biomedi | Biomedi | 04.10.04 18:45 | ||
| Geron (902213) weitere + 7%! o. T. | Biomedi | 07.06.04 14:51 |